Bluebird bio Inc (BLUE)

Name: Bluebird bio Inc (BLUE) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Bluebird bio Inc (BLUE)

Stock Card

$4.97

$0.00 (0.00%)

As on 02-Jun-2025 09:30EDT

Market cap

$49 Mln

Revenue (TTM)

$104 Mln

P/E Ratio

P/B Ratio

0.7

Div. Yield

0 %

Bluebird bio Inc (BLUE) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.97 High: 4.97

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.5
Debt to Equity

0
Book Value

$--
EPS

$-5.6
Face value

--
Shares outstanding

9,792,460

10 Years Aggregate

CFO

$-3,342.56 Mln

EBITDA

$-3,644.16 Mln

Net Profit

$-3,698.95 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Bluebird bio Inc (BLUE)	-40.4	22.7	21.8	-72.5	-56.3	-64.1	-46.3
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Jun-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Bluebird bio Inc (BLUE)	-69.5	-80.1	-30.7	-64.3	-50.7	-11.5	-44.1
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Bluebird bio Inc (BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO... (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private. Read more

President, CEO & Director

Mr. Andrew Obenshain
President, CEO & Director

Mr. Andrew Obenshain
Headquarters

Somerville, MA
Website

https://www.bluebirdbio.com

FAQs for Bluebird bio Inc (BLUE)

What is the current share price of Bluebird bio Inc (BLUE) Today?

The share price of Bluebird bio Inc (BLUE) is $4.97 (NASDAQ) as of 02-Jun-2025 09:30 EDT. Bluebird bio Inc (BLUE) has given a return of -56.26% in the last 3 years.

What is the current PB & PE ratio of Bluebird bio Inc (BLUE)?

Since, TTM earnings of Bluebird bio Inc (BLUE) is negative, P/E ratio is not available.
The P/B ratio of Bluebird bio Inc (BLUE) is 0.73 times as on 02-Jun-2025, a 86 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-2.22	-16.96
2023	-0.06	0.07
2022	-2.21	3.00
2021	-1.29	1.94
2020	-4.64	2.12

What is the 52 Week High and Low of Bluebird bio Inc (BLUE)?

The 52-week high and low of Bluebird bio Inc (BLUE) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Bluebird bio Inc (BLUE)?

Bluebird bio Inc (BLUE) has a market capitalisation of $ 49 Mln as on 02-Jun-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Bluebird bio Inc (BLUE)?

Before investing in Bluebird bio Inc (BLUE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.